Welcome to our dedicated page for Unity Biotechnology news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Biotechnology stock.
Unity Biotechnology, Inc. (NASDAQ: UBX) is a leading biotechnology company focused on developing innovative therapeutics aimed at extending human healthspan by targeting age-related diseases. The company's pioneering approach centers on creating senolytic medicines, which selectively eliminate senescent cells – cells that contribute to aging and various diseases. Unity's initial efforts are directed toward treating conditions such as osteoporosis, eye diseases, and pulmonary diseases.
Unity’s main drug candidates include:
- UBX1325: A promising treatment for age-related eye diseases, including diabetic macular edema (DME). UBX1325 recently demonstrated positive results in the Phase 2 ENVISION study, maintaining vision gains and significantly reducing anti-VEGF treatment needs in patients with wet AMD.
- UBX2089: A circulating hormone being studied for multiple neurological conditions.
- UBX2050: Another investigational drug aimed at age-associated diseases.
Recently, Unity announced the successful results from Part B of the Phase 2 ENVISION study for UBX1325, highlighting its safety and efficacy in maintaining visual acuity and reducing the treatment burden for patients with wet AMD who were not receiving optimal benefits from ongoing anti-VEGF therapy. The study showed that 40% of UBX1325-treated patients did not require anti-VEGF rescue through 48 weeks.
Unity's current focus is on its DME program, where UBX1325 showed a statistically significant improvement in visual acuity during the Phase 2 BEHOLD study. The company has initiated a Phase 2b study and plans to randomize the first patient in Q4 2023. Additional data from the ENVISION study is expected to be presented at upcoming medical conferences.
About the ENVISION Study: The Phase 2 ENVISION study is a multi-center, randomized, double-masked, active-controlled study evaluating the safety, tolerability, efficacy, and durability of UBX1325 in combination with aflibercept for patients with neovascular AMD.
For more detailed information, visit www.unitybiotechnology.com.
UNITY Biotechnology (NASDAQ: UBX) announced promising 12-week results from its Phase 1 study of UBX1325 for diabetic macular edema (DME) and age-related macular degeneration (AMD). The study showed sustained improvement in vision and retinal structure after a single injection, with 8 of 12 patients experiencing gains in best-corrected visual acuity (BCVA). The treatment was well tolerated, with no serious adverse events reported. With 24-week data expected by year-end, UBX1325 could offer a vital alternative for patients unresponsive to traditional therapies.
UNITY Biotechnology announced its participation in several virtual investor conferences in September 2021. Key events include:
- 16th Annual Citi BioPharma Conference on September 8
- Morgan Stanley 19th Annual Global Healthcare Conference on September 9
- 23rd H.C. Wainwright Global Investment Conference from September 13
- Cantor Virtual Global Healthcare Conference on September 29
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 – UNITY Biotechnology, Inc. (NASDAQ: UBX) announced that from August 3 to August 17, 2021, its Compensation Committee granted stock-based awards covering 49,000 shares of common stock to 2 new employees. These awards were made under the UNITY 2020 Employment Inducement Incentive Plan, approved by the Board in March 2020, to attract new talent in compliance with Nasdaq rules. UNITY is focused on developing therapeutics that target aging-related diseases through the elimination of senescent cells.
SOUTH SAN FRANCISCO, Calif., August 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, a biotechnology firm focused on therapeutics to combat aging-related diseases, announced its participation in the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. CEO Anirvan Ghosh, Ph.D., will join a panel discussing future advancements in vision repair, enhancing understanding beyond traditional therapies. A live audio webcast will be available on UNITY’s website, with an archived replay accessible for 90 days.
UNITY Biotechnology reported promising Phase 1 results for UBX1325, targeting diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The study showed a favorable safety profile with most patients experiencing improvements in visual acuity and retinal structure. As of June 30, 2021, cash and equivalents total $97.5 million, expected to fund operations through Q3 2022. Operating loss decreased to $17.0 million from $23.3 million year-over-year, while R&D expenses dropped significantly due to cost-cutting measures.
Ascentage Pharma has announced a milestone payment of US$2 million from its licensee, UNITY Biotechnology (NASDAQ:UBX), following positive Phase I clinical data for UBX1325, a Bcl-xL inhibitor aimed at advanced vascular eye diseases. The study showed that most patients with advanced diabetic macular edema or wet age-related macular degeneration improved rapidly after treatment. The first patient has also been dosed in the subsequent Phase IIa study, indicating significant progress in the clinical development of senolytic therapeutics.
UNITY Biotechnology announced the grant of stock-based awards to 3 new employees, totaling 41,900 shares of its common stock, from July 13 to July 27, 2021. These awards were granted under the UNITY 2020 Employment Inducement Incentive Plan, which aims to attract new talent as a material inducement for employment, in compliance with Nasdaq rules. The company focuses on developing therapeutics aimed at aging-related diseases, particularly targeting senescent cells to benefit age-related ophthalmologic and neurologic conditions.
UNITY Biotechnology announced a conference call on July 27, 2021, to discuss initial safety and efficacy data for UBX1325 in treating diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Dr. Robert Bhisitkul will present insights on clinical improvements in visual acuity and retinal structure observed in trial subjects. Preliminary data indicated rapid enhancements in best-corrected visual acuity and reductions in retinal fluid. UNITY aims to further explore UBX1325's potential as a disease-modifying treatment alongside existing therapies.
UNITY Biotechnology announced positive Phase 1 safety study results for UBX1325, a novel senolytic therapeutic for diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The treatment showed significant improvements in best-corrected visual acuity and retinal structure without adverse side effects, indicating its potential as an alternative to anti-VEGF therapies. The company initiated a Phase 2a study to further assess UBX1325's efficacy, with data expected in the first half of 2022, highlighting its potential benefits for patients unresponsive to current treatments.
UNITY Biotechnology [NASDAQ: UBX] announced the grant of stock-based awards totaling 9,000 shares from May 18 to June 1, 2021, to a new employee. This grant follows the UNITY 2020 Employment Inducement Incentive Plan approved in March 2020, aimed at incentivizing new hires. The company's focus remains on developing therapeutics designed to modify or eliminate senescent cells in age-related diseases, particularly within ophthalmology and neurology.
FAQ
What is the current stock price of Unity Biotechnology (UBX)?
What is the market cap of Unity Biotechnology (UBX)?
What is Unity Biotechnology's primary focus?
What diseases is Unity Biotechnology targeting?
What is UBX1325?
What were the latest results from the ENVISION study?
What are the current projects of Unity Biotechnology?
Where can I find more information about Unity Biotechnology?
What is the significance of senolytic medicines?
Has UBX1325 been approved for use?
What is the expected timeline for the ASPIRE study?
What partnerships does Unity Biotechnology have?
